Evotec stock falls again as weak half-year figures and guidance weigh on sentiment
Published on 09/04/2026 at 18:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock (ISIN DE0005664809) is under renewed pressure on Xetra, with the shares changing hands at around 3.22 EUR as of September 4, 2026, down about 1.7 percent in the afternoon session according to finanzen.ch and intraday data from Quotrix.
Stock hovers near 52-week low
According to finanzen.ch, Evotec shares were quoted at 3.22 EUR on Xetra at 16:28 as of September 4, 2026, representing a loss of 1.7 percent on the day after opening at 3.27 EUR.
Intraday data from Quotrix show parallel trading indications with Evotec at around 3.22 EUR in early dealings, underlining that the stock is currently struggling to gain traction across German trading venues.
Weak first-half 2026 figures and cut guidance
The pressure on Evotec stock is closely tied to the company’s latest financial figures and guidance. As reported by Boerse Express on September 4, 2026, Evotec recently presented its final numbers for the first half of 2026 and confirmed a lowered full-year outlook.
In the second quarter of 2026, revenue fell by 16.2 percent to 143.5 million EUR compared with the same period a year earlier, underscoring the operational strain in the company’s core discovery and development services.
For the full first half of 2026, Evotec’s revenue declined by 19.2 percent year on year to 300.1 million EUR, according to Boerse Express, highlighting that the weakness is not confined to a single quarter but spans the broader period.
The earnings picture is also challenging. Adjusted EBITDA for the first half of 2026 came in at minus 42.7 million EUR, marking a clear deterioration from the prior-year profitability and signaling that the business is currently loss-making at the operating level.
Management has responded by sharply cutting full-year guidance. For fiscal year 2026, Evotec now forecasts revenue between 570 million and 610 million EUR, down from an earlier range of 700 million to 780 million EUR that had implied continued growth.
On the earnings side, the company now expects an adjusted EBITDA loss of between 70 million and 105 million EUR for 2026, whereas previously Evotec had guided to a potential adjusted EBITDA profit of up to 40 million EUR. The shift from a possible profit to a clearly loss-making corridor is a central reason for investors’ caution.
Boerse Express notes that the stock price moved lower in response to these figures, registering a decline of 2.7 percent over the subsequent week. That reaction suggests that, while some of the downgrade may have been anticipated, the scale of the guidance cut still led to incremental selling.
Evotec stock and company figures at a glance
Investors who want to follow Evotec stock more closely can find a compact overview of current price data and past articles via the ISIN, while Evotec's own investor relations materials provide the detailed financials behind the latest guidance changes.
Distance to yearly highs and TecDAX environment
The weak guidance and declining earnings also show up clearly in Evotec’s longer-term share performance. Boerse Express points out that Evotec shares recently touched a 52-week low of 3.14 EUR on September 2, 2026, leaving the current level of around 3.22 EUR only about 2.5 percent above that low.
By contrast, the stock’s high for the current period is much higher. Evotec reached a recent year high of 7.75 EUR on November 5, 2025, and the current price is approximately 58 percent below that mark, illustrating just how much market confidence has eroded over the past months.
Evotec is part of the German TecDAX index, which groups technology and biotech names listed in Germany. In that environment, the pronounced drop in Evotec stock stands out, as some peers have shown more resilient price behavior while Evotec continues to trade close to its technical floor.
For investors, the combination of a nearly 20 percent revenue decline in the first half of 2026, an operating loss and a guidance corridor pointing to further losses provides a clear explanation for why Evotec stock is underperforming within the TecDAX universe.
Representative segment and partnerships
Evotec’s business model is built around providing discovery and development services to pharmaceutical and biotech partners, spanning areas such as small molecules, biologics and cell-based therapies. A key segment is its research and development collaborations in oncology and immunology, where the company has built a pipeline of partnered assets.
Recent coverage on ad-hoc-news.de has highlighted a new T-cell research alliance targeting solid tumors as an example of Evotec’s focus on advanced cell-based therapies. While such partnerships can unlock long-term value, the immediate financial impact depends on milestones and service revenues that have not fully offset the current downturn in other parts of the portfolio.
For retail investors, this means that Evotec’s product and partnership pipeline remains an important qualitative factor, but the near-term share price is being driven more by the hard numbers of revenue, EBITDA and guidance than by the promise of future projects.
Evotec stock price as of September 4, 2026
Across German trading venues, Evotec stock is currently consolidating slightly above its freshly set 52-week low. Based on intraday Xetra data from finanzen.ch, the shares traded at 3.22 EUR at 16:28 on September 4, 2026, down 1.7 percent on the session after starting the day at 3.27 EUR and briefly dipping to 3.19 EUR.
That narrow distance to the 52-week low of 3.14 EUR reached on September 2, 2026, and the roughly 58 percent gap to the 7.75 EUR high recorded on November 5, 2025, encapsulate the current risk-reward profile of Evotec stock: the valuation reflects significant caution, while any sustained recovery would likely require a visible turnaround in revenue trends and a path back toward positive adjusted EBITDA.
Evotec stock fact box
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of September 4, 2026, 16:28): 3.22 EUR
- Market capitalization: 560,000,000 EUR (as of September 4, 2026)
- Sector / Industry: Biotechnology / Life Sciences
- Index membership: TecDAX
